AB521 在肾细胞癌和其他实体瘤中的 1 期研究 (ARC-20)
一项 1 期、开放标签、剂量递增和剂量扩展研究,旨在研究 AB521 单一疗法在患有透明细胞肾细胞癌和其他实体瘤的参与者中的安全性、耐受性和药代动力学特征
The purpose of this study is to evaluate the safety and tolerability of:
- casdatifan when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and
- casdatifan monotherapy and casdatifan in combination with cabozantinib or zimberelimab or zimberelimab and ipilimumab or tivozanib or ivonescimab or zimberelimab and axitinib in participants with ccRCC in the dose expansion stage.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Medical Director
- 电话号码:+1-510-462-3330
- 邮箱:ClinicalTrialInquiry@arcusbio.com
学习地点
-
-
-
Camperdown、澳大利亚
- 尚未招聘
- Research Site
-
Melbourne、澳大利亚
- 招聘中
- Research Site
-
Sydney、澳大利亚
- 招聘中
- Research Site
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- 招聘中
- Research Site
-
-
California
-
San Diego、California、美国、92093
- 招聘中
- Research Site
-
Santa Monica、California、美国、90404
- 招聘中
- Research Site
-
-
Florida
-
Miami、Florida、美国、33136
- 招聘中
- Research Site
-
-
Georgia
-
Atlanta、Georgia、美国、30322-1013
- 招聘中
- Research Site
-
-
Kentucky
-
Louisville、Kentucky、美国、40202
- 招聘中
- Research Site
-
-
Louisiana
-
New Orleans、Louisiana、美国、70121
- 招聘中
- Research Site
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- 招聘中
- Research Site
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Research Site
-
-
Michigan
-
Detroit、Michigan、美国、48202
- 招聘中
- Research Site
-
Detroit、Michigan、美国、48201
- 招聘中
- Research Site
-
-
Nebraska
-
Omaha、Nebraska、美国、68124
- 招聘中
- Research Site
-
-
New York
-
New York、New York、美国、10065
- 招聘中
- Research Site
-
New York、New York、美国、10029
- 招聘中
- Research Site
-
-
Ohio
-
Cleveland、Ohio、美国、44106
- 招聘中
- Research Site
-
Cleveland、Ohio、美国、44195
- 招聘中
- Research Site
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、美国、15232
- 招聘中
- Research Site
-
-
Tennessee
-
Nashville、Tennessee、美国、37203
- 招聘中
- Research Site
-
Nashville、Tennessee、美国、37240
- 招聘中
- Research Site
-
-
Texas
-
San Antonio、Texas、美国、78229
- 招聘中
- Research Site
-
-
-
-
-
Barcelona、西班牙
- 招聘中
- Research Site
-
-
-
-
-
Seoul、韩国
- 招聘中
- Research Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
-
Must have at least one measurable lesion per RECIST guidance
-
Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 1
-
Disease-specific criteria for dose escalation:
- Participants may have any pathologically confirmed solid tumor type where no other treatment options are available
- Creatinine clearance ≥ 40 mL/min
Disease-specific criteria for dose-expansion:
- Histologically confirmed ccRCC
- Creatinine clearance ≥ 40 mL/min
Key Exclusion Criteria:
- Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product
- Has any other clinically significant cardiac, respiratory, or other medical or psychiatric condition that might interfere with a participant's participation in the clinical study or make the administration of investigational product hazardous
- History of trauma or major surgery within 28 days prior to the first dose of investigational product
- For all expansion cohorts: prior treatment with an hypoxia inducible factor (HIF)-2α inhibitor (except for the tivozanib +/- casdatifan cohort). For the casdatifan + cabozantinib combination cohort, any prior treatment with cabozantinib. For casdatifan + zimberelimab and casdatifan + zimberelimab + ipilimumab cohorts, any prior systemic treatment when cancer is present.
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose Escalation Cohort 1
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Escalation Cohort 2
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Escalation Cohort 3
Participants will receive casdatifan orally twice daily |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Escalation Cohort 4
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Escalation Cohort 5
Participants will receive casdatifan orally once daily |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 1
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 2
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 3
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 4
Participants will receive casdatifan orally with with cabozantinib orally |
Administered as specified in the treatment arm Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 5
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 6
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 7
Participants will receive casdatifan orally with zimberelimab infusion |
Administered as specified in the treatment arm
其他名称:
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 8
Participants will receive casdatifan orally |
Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 9
Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion |
Administered as specified in the treatment arm
其他名称:
Administered as specified in the treatment arm Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 10
Participants will receive casdatifan orally with zimberelimab infusion and ipilimumab infusion |
Administered as specified in the treatment arm
其他名称:
Administered as specified in the treatment arm Administered as specified in the treatment arm
其他名称:
|
|
实验性的:Dose Expansion Cohort 11
Participants will receive casdatifan orally with tivozanib orally or tivozanib orally only. |
Administered as specified in the treatment arm
其他名称:
Administered as specified in the treatment arm |
|
实验性的:Dose Expansion Cohort 12
Participants will receive casdatifan orally with ivonescimab infusion. |
Administered as specified in the treatment arm
其他名称:
Administered as specified in the treatment arm |
|
实验性的:Dose Expansion Cohort 13
Participants will receive casdatifan orally with zimberelimab infusion and axitinib orally. |
Administered as specified in the treatment arm
其他名称:
Administered as specified in the treatment arm
其他名称:
Administered as specified in the treatment arm |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
具有剂量限制毒性 (DLT) 的参与者人数
大体时间:长达 4 个月
|
长达 4 个月
|
|
发生不良事件 (AE) 的参与者人数
大体时间:长达 4 个月
|
长达 4 个月
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
根据实体瘤反应评估标准 (RECIST) v1.1 测量的客观反应率
大体时间:长达 4 个月
|
长达 4 个月
|
|
卡达替凡的血浆浓度
大体时间:长达 4 个月
|
长达 4 个月
|
|
卡达替芬的血浆浓度时间曲线下面积(AUC)
大体时间:长达 4 个月
|
长达 4 个月
|
|
卡达替芬的最大观察血浆浓度 (Cmax)
大体时间:长达 4 个月
|
长达 4 个月
|
|
Duration of Response as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
大体时间:Up to 4 months
|
Up to 4 months
|
|
Progression-free survival as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
大体时间:Up to 4 months
|
Up to 4 months
|
|
Overall survival
大体时间:Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with tivozanib
大体时间:Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with tivozanib
大体时间:Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with ivonescimab
大体时间:Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with ivonescimab
大体时间:Up to 4 months
|
Up to 4 months
|
|
Percentage of patients who are ADA-positive and ADA-negative against ivonescimab
大体时间:Up to 4 months
|
Up to 4 months
|
|
Area under the plasma concentration time curve (AUC) of casdatifan in combination with zimberelimab and axitinib
大体时间:Up to 4 months
|
Up to 4 months
|
|
Maximum Observed Plasma Concentration (Cmax) of casdatifan in combination with zimberelimab and axitinib
大体时间:Up to 4 months
|
Up to 4 months
|
合作者和调查者
调查人员
- 研究主任:Medical Director、Arcus Biosciences
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
- 泌尿生殖系统疾病
- 泌尿生殖系统肿瘤
- 按部位分类的肿瘤
- 肿瘤
- 男性泌尿生殖系统疾病
- 肾脏疾病
- 泌尿系统疾病
- 女性泌尿生殖系统疾病
- 女性泌尿生殖系统疾病和妊娠并发症
- 组织学类型的肿瘤
- 肿瘤、腺体和上皮
- 腺癌
- 泌尿系肿瘤
- 癌
- 癌,肾细胞
- 肾脏肿瘤
- 红细胞增多症,家族性,4
- 氨基酸,肽和蛋白质
- 蛋白质
- 有机化学品
- 杂环化合物,1形
- 杂环化合物
- 杂环化合物,2环
- 杂环化合物,融合环
- Azoles
- 碳氢化合物
- 碳氢化合物,循环
- 羧酸
- 碳氢化合物,芳香族
- 酰胺
- 抗体,单克隆,人源化
- 抗体,单克隆
- 抗体
- 免疫球蛋白
- 免疫蛋白
- 血蛋白
- 血清球蛋白
- 球蛋白
- 苯衍生物
- 酸,碳环
- 苯甲酸盐
- 苯甲酰基
- 吲唑
- 吡唑唑
- 阿昔替尼
- 易普利姆玛
- Zimberelimab
- 卡巴替尼
- tivozanib
其他研究编号
- ARC-20
- 2024-519142-70-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Arcus will provide access to individual de-identified participant data and related study documents [e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)] upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
For more information, please visit our website.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.